Asia Fresh News

Asia Fresh Stories

Mundipharma Appointed as Development and Marketing Partner for flutiform(R) in Mexico, Central and South America

leave a comment »

SINGAPORE /PRNewswire/ — Mundipharma International Corporation Limited has announced that it has entered into agreements with Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, and Sanofi Winthrop Industrie (“Sanofi”) to transfer the exclusive development, licensing and marketing rights for flutiform® for Mexico, Central and South America (“Territory”) to the Mundipharma network of independent associated companies (“Mundipharma”).

Mundipharma already has exclusive development, licensing and marketing rights for flutiform® in most markets outside Japan and the Americas.  flutiform®, the novel combination of the fast-acting long-acting beta agonist (LABA), formoterol, and the most widely prescribed inhaled corticosteroid (ICS), fluticasone, has been launched and is being marketed successfully by Mundipharma in 29 countries and Mundipharma now intends to leverage this experience in the Territory. Sanofi has obtained approvals for the product in Argentina and Colombia and has agreed to transfer these registrations to Mundipharma.

The transfer to Mundipharma follows a review by Sanofi of its strategy in the region and has been implemented by mutual agreement.  It has been effected by way of novation of the original development, licensing and marketing agreement which Skyepharma agreed with Sanofi in 2011.  Subject to minor adjustments, the terms of the novated agreement remain the same.

This transfer has no effect on the contract manufacturing arrangement whereby the Sanofi group manufacturesflutiform®, for Skyepharma in its factory in Holmes Chapel, UK.

Raman Singh, President, Mundipharma Asia Pacific, Latin America, Middle East and North Africa, said:

Asthma has a significant impact on people’s quality of life by affecting the most essential function: the ability to breathe. We at Mundipharma have been focused on developing new and innovative asthma treatment options, and this partnership will enable us to leverage our growing success with flutiform® in the Latin American region.  In the many markets where we have launched flutiform®, we have found that it offers a valuable treatment option for patients whose asthma symptoms are not adequately controlled and we believe this will also be the case in Mexico, Central and South America.”

Peter Grant, Chief Executive Officer of Skyepharma, commented:

“Mundipharma has made very good progress with flutiform® in markets around the world and we welcome the opportunity to further extend our partnership with its international network.  Mundipharma is in an excellent position to leverage its substantial experience with flutiform® and to bring this important new treatment option to patients inMexico, Central and South America.”

®: flutiform is a Registered Trademark

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as severe pain, oncology, respiratory disease rheumatoid arthritis, antiseptics and laxatives.

For more information please visit:

About Skyepharma

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products.  The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses.  The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies.

For more information, visit

Logo –

Source: Mundipharma Pte Ltd

Related stocks: LSE:SKP OTC-PINK:SKYEY

Written by asiafreshnews

January 29, 2016 at 2:02 pm

Posted in Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: